Temozolomide as a Single Agent or in Combination for Patients with High Risk Refractory or Relapsed Neuroblastoma: Excellent Tolerance and Sustained Disease Responses

被引：0
|
作者：
Metayer, L. [1 ]
Annereau, M. [2 ]
Abbas, R. [3 ]
Hinterlang, M. [2 ]
Schleiermacher, G. [4 ]
Defachelles, A. S. [5 ]
Pasqualini, C. [1 ]
Berlanga, P. [1 ]
Vassal, G. [6 ]
Valteau-Couanet, D. [1 ]
机构：
[1] Gustave Roussy, Dept Childhood & Adolescent Oncol, Villejuif, France
[2] Gustave Roussy, Dept Pharm, Villejuif, France
[3] Gustave Roussy, Dept Biostat & Epidemiol, Villejuif, France
[4] Inst Curie, Dept Paediat Oncol, Paris, France
[5] Ctr Oscar Lambret, Dept Paediat Oncol, Lille, France
[6] Gustave Roussy, Dept Clin Res, Villejuif, France
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP052 SIOP
引用
收藏
页码：S33 / S34
页数：2
相关论文
共 50 条
  • [21] Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone
    Sokol, Elizabeth
    Haut, Paul R.
    Gosiengfiao, Yasmin
    Feinstein, Kate
    Pytel, Peter
    Cohn, Susan L.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (03) : 512 - 514
  • [22] Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa K.
    Tornoe, Karen
    Kushner, Brian H.
    CANCER REPORTS, 2023, 6 (01)
  • [23] Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes
    Prebet, Thomas
    Braun, Thorsten
    Beyne-Rauzy, Odile
    Dreyfus, Francois
    Stammatoullas, Aspasia
    Wattel, Eric
    Ame, Shanti
    Raffoux, Emmanuel
    Delaunay, Jacques
    Charbonnier, Aude
    Ades, Lionel
    Fenaux, Pierre
    Vey, Norbert
    LEUKEMIA RESEARCH, 2014, 38 (01) : 29 - 33
  • [24] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
    Elter, T.
    James, R.
    Busch, R.
    Winkler, D.
    Ritgen, M.
    Boettcher, S.
    Kahl, C.
    Gassmann, W.
    Stauch, M.
    Hasan, I.
    Staib, P.
    Fischer, K.
    Fink, A-M
    Bahlo, J.
    Buehler, A.
    Doehner, H.
    Wendtner, C-M
    Stilgenbauer, S.
    Engert, A.
    Hallek, M.
    LEUKEMIA, 2012, 26 (12) : 2549 - 2552
  • [25] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
    T Elter
    R James
    R Busch
    D Winkler
    M Ritgen
    S Böttcher
    C Kahl
    W Gassmann
    M Stauch
    I Hasan
    P Staib
    K Fischer
    A-M Fink
    J Bahlo
    A Bühler
    H Döhner
    C-M Wendtner
    S Stilgenbauer
    A Engert
    M Hallek
    Leukemia, 2012, 26 : 2549 - 2552
  • [26] Survival and palliative care decision making in high-risk neuroblastoma patients with refractory or relapsed disease: Experience from two paediatric oncology centres in the UK
    Ramanujachar, Ramya
    Marshall, Lynley
    Delany, Judith
    Brock, Penelope
    Pritchard-Jones, Kathy
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 568 - 568
  • [27] Naxitamab and granulocyte macrophage colony stimulating factor (GM- CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.
    Chan, Godfrey Chi-Fung
    Hindsberger, Charlotte
    Morsing, Anni
    Lisby, Steen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
    Metzeler, Klaus H.
    Winer, Eric S.
    Platzbecker, Uwe
    Verma, Amit
    DeAngelo, Daniel J.
    Tarantolo, Stefano R.
    Sallman, David A.
    Dugan, James
    Groepper, Stefanie
    Goetze, Katharina S.
    Li, Chia-Cheng
    Zhao, Wanying
    Lane, Maureen
    von Roemeling, Reinhard
    Carlisle, Samantha
    Weigert, Anne
    Boehme, Matthias
    Kubasch, Anne Sophie
    Garcia-Manero, Guillermo
    BLOOD, 2022, 140 : 9048 - 9049
  • [29] Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2
    Siebert, Nikolai
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Zumpe, Maxi
    Wegner, Danilo
    Kietz, Silke
    Ehlert, Karoline
    Veal, Gareth J.
    Siegmund, Werner
    Weiss, Michael
    Loibner, Hans
    Ladenstein, Ruth
    Lode, Holger N.
    MABS, 2016, 8 (03) : 604 - 616
  • [30] Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features
    Vigil, Carlos
    Jahan, Nusrat
    Paun, Oana
    Weis, Jennifer
    Heckman, Kevin
    Silverman, Margarida
    Carter, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S297 - S297
12345